Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection

• Published in: The Lancet infectious diseases Vol. 23; no. 6; pp. e218 - e226
• Main Authors: Stafford, Adam, Rimmer, Stephanie, Gilchrist, Mark, Sun, Kristi, Davies, Ella P, Waddington, Claire S, Chiu, Christopher, Armstrong-James, Darius, Swaine, Thomas, Davies, Frances, Gómez, Carlos H M, Kumar, Vagish, ElHaddad, Ahmad, Awad, Zaid, Smart, Christopher, Mora-Peris, Borja, Muir, David, Randell, Paul, Peters, Joanna, Chand, Meera, Warrell, Clare E, Rampling, Tommy, Cooke, Graham, Dhanji, Sara, Campbell, Vivienne, Davies, Carys, Osman, Sana, Abbara, Aula
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.06.2023; Elsevier Limited
• Subjects: Angina; Antiviral Agents - therapeutic use; Antiviral drugs; Bacterial infections; Biopsy; Cidofovir; Cidofovir - therapeutic use; Cytosine - therapeutic use; Disease; Epidemics; Grand Round; HIV; HIV Infections - complications; HIV Infections - drug therapy; Hospitals; Human immunodeficiency virus; Humans; Infectious diseases; Intravenous administration; Lesions; Ludwig's angina; Lymphocytes; Male; Medical imaging; Middle Aged; Monkeypox; Mpox (monkeypox) - drug therapy; Organophosphonates - therapeutic use; Ostomy; Patients; Skin diseases; Skin lesions; Staphylococcus infections; State Medicine; Tongue; United Kingdom > UK; Africa
• ISSN: 1473-3099; 1474-4457; 1474-4457
• DOI: 10.1016/S1473-3099(23)00044-0

A 48-year-old man with poorly controlled HIV presented with severe human monkeypox virus (hMPXV) infection, having completed 2 weeks of tecovirimat at another hospital. He had painful, ulcerating skin lesions on most of his body and oropharyngeal cavity, with subsequent Ludwig's angina requiring repeated surgical interventions. Despite commencing a second, prolonged course of tecovirimat, he did not objectively improve, and new lesions were still noted at day 24. Discussion at the UK National Health Service England High Consequence Infectious Diseases Network recommended the use of 3% topical and then intravenous cidofovir, which was given at 5 mg/kg; the patient made a noticeable improvement after the first intravenous dose. He received further intravenous doses at 7 days and 21 days after the dose and was discharged at day 52. Cidofovir is not licensed for use in treatment of hMPXV infection. Data for cidofovir use in hMPXV are restricted to studies in animals. Four other documented cases of cidofovir use against hMPXV have been reported in the USA in 2022, but we present its first use in the UK. The scarcity of studies into the use of cidofovir in this condition clearly shows the need for robust studies to assess efficacy, optimum dosage, timing, and route of administration.